Proliferating Cell Nuclear Antigen in Needle Biopsy Specimens of Prostatic Carcinoma

Naito, Seiji; Sakamoto, Naotaka; Kotoh, Shuji; Goto, Ken; Koga, Hirofumi; Hasegawa, Shuji; Matsumoto, Tetsuro; Kumazawa, Joichi

doi:10.1159/000475369

Cited by 9 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the utility of these markers can be confirmed in RP specimens by other studies, the next step would be to use the same prognosticators in prostate needle‐biopsy specimens. In one study a significant difference in the PCNA index according to the growth pattern, nuclear anaplasia and clinical stage was reported in needle‐biopsy specimens [29]. In a multivariate analysis, the PCNA LI was an independent prognostic variable.…”

Section: Discussionmentioning

confidence: 99%

Proliferating‐cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki‐67

Taftachi¹,

Ayhan

Ekici³

et al. 2005

BJU International

View full text Add to dashboard Cite

proliferation, 1000 cells were counted at ¥ 400 magnification by two observers and the percentage of tumour cells positively stained with Ki-67 and PCNA defined as the Ki-67 and PCNA labelling index (LI), respectively. The two LI were compared in the NM and M groups, and the correlation of the LIs with pathological stage, progression and prostatespecific antigen (PSA)-free survival evaluated. Prognostic values of the LI were analysed using multivariate analysis. RESULTSThe mean (range) follow-up was 33 (4-78) months. The mean LIs were higher in the M than the NM group for both PCNA and Ki-67 ( P = 0.02 and 0.019, respectively). Both LIs were markedly different between the groups when stratified by progression, with both significantly higher in men with progression in the NM group. Both LIs had a significant association with Gleason score, pathological stage, progression and PSA-free survival. In multivariate analysis the PCNA LI, surgical margin status and pathological stage were independent factors for progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Proliferating‐cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki‐67

Taftachi¹,

Ayhan

Ekici³

et al. 2005

BJU International

View full text Add to dashboard Cite

show abstract

“…Similarly, Warzynski et al [36] found with flow cytometry that 40% of PC patients receiving radical prostatectomy had a different DNA ploidy depending upon which area was sampled. However, Naito et al [37] reported that PCNA immunostaining of needle biopsy specimens of PC could be an objective and quantitative means for evaluating the bio logical malignancy of PC. In the present study, we have made an effort to analyze the change of the immunostainings during the treatment in almost the same cancerous areas using TRUS and/or TRUS-guided prostatic biopsy or by comparing the localization of the cancerous tissue in the specimen obtained at radical prostatectomy with pre treatment TRUS.…”

Section: Relationship Of Pcna and Nm23 Protein With Serum Testosteronmentioning

confidence: 99%

Relationship of Serum Testosterone Level with Proliferating Cell Nuclear Antigen and nm23 Protein in Human Prostatic Carcinoma Tissue

Shiina¹,

Igawa²,

Shigeno³

et al. 1997

Oncology

View full text Add to dashboard Cite

Objective: To elucidate the biological significance of proliferating cell nuclear antigen (PCNA) and nm23 immunoreactivity in prostatic carcinoma (PC) tissue, both expressions were immunohistochemically analyzed, and the results were compared with the change of the serum testosterone (T) level. Methods: The paraffin-embedded materials obtained from 49 untreated PC and 16 hormonally refractory PC (hr-PC) were used. Of the 49 untreated PC, 35 received luteinizing hormone-releasing hormone (LH-RH) analogue treatment, while 14 received a cisplatin-based chemotherapy. The immunohistochemistry of PCNA and nm23 protein was performed using an anti-PCNA monoclonal antibody (PC-10) and an antihuman nm23 polyclonal antibody (OA-11-890), respectively. The serum T level was measured by means of radioimmunoassay. Results: In both untreated PC and hr-PC, the immunoreactivity of nm23 protein significantly correlated with the PCNA expression. Both PCNA expression and nm23 protein immunoreactivity were higher in poorly differentiated PC than those observed in well-differentiated PC, while no significant difference in the serum T level was observed between poorly and well-differentiated PCs. On the other hand, both PCNA expression and nm23 protein immunoreactivity were significantly higher in hr-PC than those observed in untreated PC, whereas the serum T level was significantly lower in hr-PC. In 35 PCs treated with LH-RH analogue, no significant difference in both PCNA expression and nm23 protein immunoreactivity was found between those specimens obtained before and at 3 months after the treatment, while a significant reduction of the serum T level was noted at 3 months after the treatment. Similarly, in 14 PCs treated with a cisplatin-based chemotherapy, the same change of PCNA expression and nm23 protein immunoreactivity as observed in LH-RH analogue treatment was found, while no significant difference of the serum T level was found. Conclusions: These findings appear to indicate that (1) nm23 protein immunoreactivity is interrelated with cellular proliferation in PC tissue and (2) alteration of the serum T level during a short period was not enough to explain the essential change of cellular proliferation of PC tissue, but might reflect other aspects of tumor growth such as apoptosis.

show abstract

“…Recently, it has been reported that the proliferative activity of cells can be assessed by flow cytometry, by labeled BrdU uptake, or by using monoclonal antibodies 1,2 . The proliferative activity of prostate cancer cells has been reported to correlate with risk of metastasis, probability of recurrence, and disease specific mortality 3,4 . Proliferating cell nuclear antigen (PCNA) is an auxiliary protein of DNA polymerase delta 5 and a growth factor, which is synthesized in the late G 1 to S phases of the cell cycle and may neutralize inhibitors of DNA synthesis, thus stimulating cellular DNA synthesis 6 .…”

Section: Introductionmentioning

confidence: 99%

“…1,2 The proliferative activity of prostate cancer cells has been reported to correlate with risk of metastasis, probability of recurrence, and disease specific mortality. 3,4 Proliferating cell nuclear antigen (PCNA) is an auxiliary protein of DNA polymerase delta 5 and a growth factor, which is synthesized in the late G 1 to S phases of the cell cycle and may neutralize inhibitors of DNA synthesis, thus stimulating cellular DNA synthesis. 6 Immunostaining for PCNA can be detected from paraffin-embedded specimens; therefore, it has been recognized as a readily accessible antigen.…”

Section: Introductionmentioning

confidence: 99%

Clinical validity of proliferating cell nuclear antigen as an objective marker for evaluating biologic features in patients with untreated prostate cancer

et al. 2006

View full text Add to dashboard Cite

Background : Although Gleason grading may be the most useful system for evaluating biological activity of untreated prostate cancer, lack of interobserver validity with Gleason scores (GS) is an unsolved issue. In this study, the proliferating cell nuclear antigen labeling index (PCNA LI) in untreated prostate cancer was investigated in order to clarify the usefulness of supplemental and objective markers for evaluating the biologic features of prostate cancer. Methods : Sixty cases of prostate cancer were randomly selected from the cancer registry in Gunma University Hospital for this study. PCNA LI were evaluated using paraffin-embedded biopsy cores taken at diagnosis. Correlation of PCNA LI with the Gleason grading system, clinical stage, serum prostate-specific antigen (PSA) levels and age were evaluated. Cumulative rates of freedom from cause-specific death were also evaluated stratified by various clinicopathologic features, including PCNA LI using Kaplan-Meier analysis. Results : Proliferating cell nuclear antigen labeling index was significantly higher in patients with PSA levels over 100 ng/mL, advanced clinical stage ( > T4, N1 or M1 disease), higher Gleason grade or with a higher GS than in those with other clinicopathologic features. The 5-year cumulative rate of death from prostate cancer was significantly higher at 62% in patients with a PCNA LI of 20 or more than those with PCNA LI of less than 20, who accounted for 4%. Conclusions : Proliferating cell nuclear antigen labeling index in combination with Gleason grading system may be of clinical value in evaluating biologic features and also in predicting cause specific survival of prostate cancer in an objective, reliable and reproducible manner.

show abstract

Proliferating Cell Nuclear Antigen in Needle Biopsy Specimens of Prostatic Carcinoma

Cited by 9 publications

References 11 publications

Proliferating‐cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki‐67

Proliferating‐cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki‐67

Relationship of Serum Testosterone Level with Proliferating Cell Nuclear Antigen and nm23 Protein in Human Prostatic Carcinoma Tissue

Clinical validity of proliferating cell nuclear antigen as an objective marker for evaluating biologic features in patients with untreated prostate cancer

Contact Info

Product

Resources

About